Evidence map›Paper›PMID 41803134›Full record

ArticleNature communications2026

CXCR4-tropic HIV-1 infection in an immunocompetent monkey model.

Nicholas R Meyerson, Vanessa L Bauer, Will T Fattor, Cody J Warren, Arturo Barbachano-Guerrero, Melisa J Weiss, Obaiah Dirasantha, Bridget L Burris, Adetunji S Adesina, Joseph L Timpona and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Nicholas R Meyerson *BioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80303, USA.
Vanessa L Bauer *BioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80303, USA.
Will T Fattor *BioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80303, USA.
Cody J WarrenBioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80303, USA.ORCID http://orcid.org/0000-0003-4101-2705
Arturo Barbachano-GuerreroBioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80303, USA.ORCID http://orcid.org/0000-0001-7483-839X
Melisa J WeissDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA.
Obaiah DirasanthaBioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80303, USA.
Bridget L BurrisDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA.
Adetunji S AdesinaBioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80303, USA.
Joseph L TimponaBioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80303, USA.
Emily R FeldmanBioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80303, USA.
Ryan T FahyBioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80303, USA.
Paul GendlerBioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80303, USA.ORCID http://orcid.org/0000-0002-2113-4564
Ava FainbergBioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80303, USA.
Pramod N NeheteDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA.
Kathryn A SheltonDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA.ORCID http://orcid.org/0000-0002-1754-1423
Analy GalvanDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA.
George W TustinDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA.
Paul J KoehleDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA.
Maria D SalinasDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA.
Omar DavilaDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA.
Elizabeth I LindemannDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA.
Sean E ClarkDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA.
Mackenzie L GarnettDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA.
C Todd DeMarcoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Salvatore R SciannaDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Thomas N DennyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Jens H KuhnIntegrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-7800-6045
Pyone P AyeTulane National Biomedical Research Center, 18703 Three Rivers Road, Covington, LA, USA.ORCID http://orcid.org/0000-0002-4764-3965
Ron S VeazeyTulane National Biomedical Research Center, 18703 Three Rivers Road, Covington, LA, USA.ORCID http://orcid.org/0000-0002-6298-2391
Sarah M KezarDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA.ORCID http://orcid.org/0000-0002-8423-0828
Gregory K WilkersonDepartment of Comparative Medicine, Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA. gwilker@email.unc.edu.ORCID http://orcid.org/0000-0002-3773-1064
Sara L SawyerBioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80303, USA. ssawyer@colorado.edu.ORCID http://orcid.org/0000-0002-6965-1085

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Breaking the Barrier to an HIV VaccineDP1AI175471 · NIAID · UNIVERSITY OF COLORADO · PI Sara Sawyer · 2022 to 2026
$5.5M
Hunting the HIV-1 UnicornDP1DA046108 · NIDA · UNIVERSITY OF COLORADO · PI SAWYER, SARA · 2018 to 2022
$4.5M
Characterizing Host-Virus Interactions in a New HIV Model OrganismR01OD034046 · OD · UNIVERSITY OF COLORADO · PI Sara Sawyer · 2022 to 2026
$3.6M
NIAID NIH HHS DP1 AI175471NIDA NIH HHS DP1 DA046108NIH HHS P51 OD011104NIH HHS R01 OD034046
6 · The paper itself

Abstract

Current animal models of HIV-1 infection are either immunocompromised or rely on proxy viruses instead of HIV-1. Here, we establish an immunocompetent animal model for CXCR4-tropic HIV-1 in owl monkeys (Aotus nancymaae). Through analysis of 191 owl monkeys, genetic characterization and functional testing demonstrate that CD4 and Tetherin in this species support HIV-1 replication. Although owl monkeys do carry restrictive TRIMCyp and APOBEC3G alleles, small changes to the HIV-1 genome allow the virus to overcome these barriers. The resulting virus remains 93% wildtype HIV-1 in sequence. Fully immunocompetent owl monkeys can be infected with this virus, recapitulating key aspects of HIV-1 infection in humans: an initial surge of virus replication, subsequent establishment of a durable set point viremia, seroconversion, and the formation of a viral reservoir. The owl monkey model broadens the experimental options for HIV-1 research, and future studies will explore its utility for CCR5-tropic virus strains.

Indexed as

AotidaeHIV-1HIV InfectionsReceptors, CXCR4AnimalsCD4 AntigensDisease Models, AnimalHumansImmunocompetenceViral TropismVirus ReplicationCD4 AntigensReceptors, CXCR4

Identifiers

PMID41803134
PMCPMC13100051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.